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Abstract
Expanded CAG/CTG repeat disorders affect over 1 in 2500 individuals worldwide. Potential therapeutic avenues include gene
silencing and modulation of repeat instability. However, there are major mechanistic gaps in our understanding of these
processes, which prevent the rational design of an efficient treatment. To address this, we developed a novel system,
ParB/ANCHOR-mediated Inducible Targeting (PInT), in which any protein can be recruited at will to a GFP reporter
containing an expanded CAG/CTG repeat. Previous studies have implicated the histone deacetylase HDAC5 and the DNA
methyltransferase DNMT1 as modulators of repeat instability via mechanisms that are not fully understood. Using PInT, we
found no evidence that HDAC5 or DNMT1 modulate repeat instability upon targeting to the expanded repeat, suggesting
that their effect is independent of local chromatin structure. Unexpectedly, we found that expanded CAG/CTG repeats
reduce the effectiveness of gene silencing mediated by targeting HDAC5 and DNMT1. The repeat-length effect in gene
silencing by HDAC5 was abolished by a small molecule inhibitor of HDAC3. Our results have important implications on the
design of epigenome editing approaches for expanded CAG/CTG repeat disorders. PInT is a versatile synthetic system to
study the effect of any sequence of interest on epigenome editing.
Introduction
There are 14 neurological and neuromuscular phenotypes
caused by the expansion of CAG/CTG repeat (1). The most
common ones are myotonic dystrophy type 1 and Huntington’s
disease. Their cellular phenotypes are caused by the expression
of an expanded allele that generates toxic RNAs and/or peptides,
which affect gene expression, splicing, and protein aggregation
in trans (2,3). These mechanisms are thought to be worsened
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by somatic expansion of the expanded allele, which occurs
in afflicted individuals over their lifetime (4). Indeed, longer
repeats cause more severe phenotypes (5,6). Currently, there is
no cure for these diseases, but modulating somatic expansion
or inducing contractions are being explored as therapeutic
approaches (4).
Expanded CAG/CTG repeats affect gene expression of the
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Figure 1. Schematic of PInT. The GFP reporter is driven by an inducible Tet-ON promoter. It contains an intron harbouring an INT sequence, which mediates the
recruitment and oligomerization of ParB. We fused ParB to ABI, a plant protein that binds PYL only in the presence of abscisic acid (ABA). The PYL construct contains
three tandem FLAG tags and the ParB-ABI fusion includes three tandem HA tags. They both contain SV40 nuclear localization signals. Fusing PYL to any protein of
interest leads to its inducible recruitment 319 bp away from a cloning site that can be used to insert a sequence of choice. Here we chose expanded CAG/CTG repeats
to test the system.
changes in expression are associated with gains in hete-
rochromatin marks, including histone H3 lysine 9 methylation
(H3K9me), HP1 binding and CpG methylation, as well as loss
of euchromatic markers, such as CTCF binding and H3 tail
acetylation (H3ac) (8–12). However, CAG/CTG repeat expansion
does not appear to alter three-dimensional chromatin confor-
mation (13).Although the heterochromatic-like state reduces the
expression of the mutant allele, it does not completely abolish it
(7). Furthermore, the remaining transcription through the repeat
tract would be expected to support repeat instability (14). Thus,
targeting the expanded allele for silencing may provide much
needed symptomatic relief.
Here we asked whether epigenome editing could be har-
nessed to modulate gene expression and CAG/CTG repeat insta-
bility. To this end,we developed a synthetic method that enables
the targeting of any peptide to a sequence of choice embedded
within the intron of a fluorescent reporter.Wenamed the system
ParB/ANCHOR-mediated induced targeting (PInT). To test our
system, we inserted CAG/CTG repeats within the reporter cas-
sette such that we could monitor both their instability as well as
their effect on gene expression. Using PInT, we clarified the role
of two heterochromatin proteins, histone deacetylase 5 (HDAC5)
and DNA methyltransferase 1 (DNMT1) in modulating repeat
instability through their local recruitment. Moreover, we show,
unexpectedly, that gene silencing efficiency brought about by
the targeting of either HDAC5 or DNMT1 is reduced at expanded
repeats compared to shorter ones. We further implicate the
catalytic activity of histone deacetylase 3 (HDAC3) in helping
expanded CAG/CTG repeats resist gene silencing. Our results
provide novel mechanistic insights into how HDAC5 and DNMT1
impact repeat instability and uncover an unexpected effect of
repeat expansion on epigenome editing.
Results
ParB/ANCHOR-mediated induced targeting (PInT)
We designed PInT (Fig. 1) to be modular and highly control-
lable. It contains a GFP mini gene that harbours two GFP
exons flanking an intron of the rat Pem1 gene (15,16). A
doxycycline-inducible promoter drives the expression of the
reporter. This cassette is always inserted at the same genomic
location as a single copy integrant on chromosome 12 of T-
Rex Flp-In HEK293 cells (13). Within the intron, we inserted
a 1029 bp non-repetitive sequence, INT, that contains four
binding sites for dimers of the Burkholderia cenocepacia ParB
protein (17). Once bound to INT, ParB oligomerizes in a sequence-
independent manner, recruiting up to 200 ParB molecules (18).
This ParB/ANCHOR system was first used in live yeast cells to
visualize double-strand break repair (17). More recently, it has
been used to monitor the mobility of a genomic locus upon
activation of transcription and to visualize viral replication of
live mammalian cells (19–21). We made the system inducible by
fusing ParB to a domain of the A. thaliana protein ABSCISIC
ACID INSENSITIVE 1 (ABI), which dimerizes with a domain
of PYRABACTIN RESISTANCE1-LIKE 1 (PYL) upon addition of
abscisic acid (ABA) to the culture medium (22). ABA is a plant
hormone that is not toxic to human cells, making its use
especially convenient. Within 319 bp of the INT sequence, there
is a cloning site that can be used to insert any DNA motif (Fig. 1).
Fusing any protein of interest to PYL allows for full temporal
control over the recruitment of a protein of interest near a DNA
sequence of choice. In this case we used a CAG/CTG repeat that
was either in the non-pathogenic (16 repeats) or pathogenic
(≥59 repeats) range. The CAG/CTG repeats affect splicing of the
reporter in a length-dependent manner, with longer repeats
leading to more robust insertion of an alternative CAG exon
that includes 38 nucleotides downstream of the CAG, creating
a frameshift (23). Thus, we can monitor repeat size as well as
changes in gene expression upon targeting any protein of choice
near a CAG/CTG repeat of various sizes.
First, we determined whether the components of PInT affect
the expression of the GFP reporter. We tested whether ABA
changed GFP expression in GFP(CAG)0 cells (15). These cells carry
the GFPmini genewithout the INT sequence and no repeat in the
intron (see Supplementary Material, Table S1 and Supplemen-
taryMaterial, Fig. S1 for details about the cell lines used and their
construction). We found that treatment with up to 500 μM of
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had no effect on GFP expression (Supplementary Material, Fig.
S2A and B). We also transiently transfected GFP(CAG)0 cells with
plasmids expressing the ParB-ABI fusion. This had no detectable
effect on GFP expression (Supplementary Material, Fig. S2C).
We next inserted the INT sequence inside the Pem1 intron and
integrated this construct using site-directed recombination, gen-
erating GFP-INT cells. These cells do not express ParB-ABI. We
found that the insertion of the INT sequence had little, if any,
discernible effect on GFP expression (Supplementary Material,
Fig. S2D).We conclude that individually the components of PInT
do not interfere with GFP expression.
We then stably integrated the ParB-ABI fusion into GFP-INT
cells to generate GFP-INT-B cells. We found a decrease in GFP
expression that correlated with higher levels of ParB-ABI (Sup-
plementary Material, Fig. S2E–G), suggesting that the binding of
ParB-ABI has a predictable effect on the expression of the GFP
reporter. Because of this, we integrated ParB-ABI early in the cell
line construction pipeline such that all the cell lines presented
here express the same amount of ParB-ABI (Supplementary
Material, Figs S1 and S3 and Supplementary Material, Table S1).
Next, we determined the efficiency of ABA-mediated tar-
geting PYL to the INT sequence and the consequences on GFP
expression and repeat instability. We used nB-Y cells, which
contain the GFPmini gene with the INT sequence, stably express
both ParB-ABI (B) and PYL (Y), and contain n CAG repeats. In
this case, we used either 16 CAG repeats, which is in the non-
pathogenic range, or an expanded repeat of 91 triplets (Fig. 2A).
Using chromatin immunoprecipitation followed by qPCR (ChIP-
qPCR), we found that only 0.02%±0.02% and 0.1%± 0.04% of
the input INT DNA could be precipitated when we treated the
cells with the solvent, DMSO, alone for 5 days in a cell line
with 16 or 91 CAG repeats, respectively (Fig. 2B). By contrast, the
addition of ABA dissolved in DMSO to the cell media increased
the association of PYL to the INT locus significantly, reaching
1.9%±0.4% and 2.5%±0.3% of the input pulled down in 16B-
Y or 91B-Y cells, respectively (Fig. 2B, P=0.002 and P=9×10−5,
comparing DMSO and ABA, for 16B-Y and 91B-Y, respectively,
using a one-way ANOVA). At the ACTA1 locus, where there is no
INT, the immunoprecipitatedDNA remained below 0.04% regard-
less of the cell line or conditions used (Fig. 2B). These results
demonstrate the inducible nature of the system and show that
the efficiency of the targeting is similar regardless of repeat size
(P=0.2 comparing ABA conditions in 91B-Y and 16B-Y lines using
a one-way ANOVA). Importantly, PYL targeting had no effect on
GFP expression as measured by flow cytometry (Fig. 2C, P=0.87
and P=0.76, when comparing the mean GFP intensities upon
DMSO or ABA treatment in 16B-Y and 91B-Y lines, respectively,
using a one-way ANOVA). Moreover, targeting PYL to expanded
CAG/CTG repeats by adding ABA to the medium of 91B-Y cells
for 30 days had no effect on the frequency of repeat instability
(Fig. 2D, Table 1, P=0.53 comparing the number of expansions,
contractions, and no change in cells treated with DMSO alone
to ABA-treated cells using a χ2 test). ABA addition, however,
decreased very slightly the magnitude of the contractions. (Sup-
plementary Material, Fig. S4A, P=0.021 using a Mann–Whitney U
test comparing cells treated with DMSO alone or with ABA). We
conclude that PInT works as an inducible targeting system and
that PYL targeting is efficient and does not further affect gene
expression or repeat instability.
Using PInT to untangle the local versus indirect roles of
chromatin modifiers
Several chromatin modifiers have been implicated in CAG/CTG
repeat expansion (reviewed in (7)). These studies relied on
knockout or knockdown of chromatin modifiers and could
not distinguish whether factors act locally at the repeat locus
(i.e. in cis), indirectly (i.e. in trans), or both. PInT is designed to
evaluate these possibilities. By fusing a chromatin modifier to
PYL, we can induce its local recruitment and ask whether repeat
instability is affected, beyond any effect its overexpression has.
The assumption is that overexpression levels are constant with
and without ABA because it is done in the same cell line. If
there is a difference in repeat instability between cells treated
with ABA and those treated with DMSO alone, then we can
conclude that the chromatin modifier acts locally. By contrast,
a modifier that acts solely indirectly, for example by altering
the transcriptome of a cell, will not show differences between
ABA- and DMSO-treated cells. PInT is deliberately designed
to compare non-targeted to targeted conditions within the
same cell line as well as between lines with different repeat
sizes but not between cell lines expressing different transgenes
(Supplementary Material, Fig. S1).
No evidence that DNMT1 impacts repeat instability by
acting in cis
DNMT1 maintains DNA methylation levels during replication
and repair (24). It has been implicated in preventing CAG/CTG
repeat expansion in the germlines of a mouse model for
spinocerebellar ataxia type 1 (25). Heterozygous Dnmt1 mice
showed lower expansion in the germlines accompanied by
changes in CpG methylation flanking the repeat tract in
testes and ovaries. High local CpG methylation correlated
with high levels of repeat instability (25), suggesting that local
levels of DNA methylation promote repeat instability. This
hypothesis predicts that targeting PYL-DNMT1 will increase
CpG methylation near the repeat tract and thereby increase
repeat expansion frequencies. Here we tested this directly
using PInT and targeted PYL-DNMT1 to 16 or 89 CAG/CTG
repeats (Fig. 3A). ChIP-qPCR confirmed robust recruitment of
PYL-DNMT1 to levels comparable to PYL alone (Fig. 3B). Indeed,
enrichment rose upon addition of ABA from 0.3%±0.1% to
5.0%±0.5% and from 0.3%±0.2% to 6.8%±0.7% in 16B-Y-DNMT1
and 89B-Y-DNMT1 cells, respectively. The recruitment was
statistically significant (P=8×10−5 and P=9×10−5 comparing
qPCR enrichment with and without ABA in 16B-Y-DNMT1 and
89B-Y-DNMT1 lines, respectively, using a one-way ANOVA).
Here again, the enrichment was not seen at the ACTA1 locus,
suggesting that it is specific to the presence of the INT sequence
(Fig. 3B). We further determined whether targeting PYL-DNMT1
could increase levels of CpG methylation near the repeat tract.
To do so, we performed bisulfite sequencing after targeting PYL-
DNMT1 for 30 days. This led to changes of 10%–20% in the levels
of CpG methylation, a modest increase (Fig. 3C), which is in line
with the weak de novo methyltransferase activity of DNMT1 (for
example see (26)). Similar changes in levels of CpG methylation
in Dnmt1 heterozygous ovaries and testes were seen to correlate
with changes in repeat instability in vivo (25).
Next, we assessed whether targeting PYL-DNMT1 promotes
repeat expansion as predicted if the hypothesis that local CpG
methylation can drive instability (25). To do so, we cultured
89B-Y-DNMT1 cells in the presence of either ABA or DMSO for
30 days, along with doxycycline to induce transcription through
the repeat tract. We found no difference in the frequency of
repeat instability or in the size of the changes between the ABA
and DMSO conditions as measured by small-pool PCR (Table 1,
Fig. 3D, Supplementary Material, Fig. S4B, P=0.78 using a χ2 test
for frequencies, P=0.77 for allele size using a Mann–Whitney U
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Figure 2. Inducible targeting of PYL at the GFP reporter. (A) Schematic representation of 16B-Y (left) and 91B-Y (right) cell lines. (B) ChIP-qPCR using antibodies against
FLAG to pull down PYL at INT and ACTA1 in 16B-Y cells (left, N=4) and 91B-Y cells (right, N=4) after 5-day treatments with ABA or DMSO. The error bars represent the
standard error. (C) Representative flow cytometry profiles after a 5-day treatment as well as quantification of the GFP expression in 16B-Y (left, N=6) and 91B-Y (right,
N=6) cells. The error bars represent the standard deviation around the mean. (D) Representative SP-PCR blots after 30 days of continuous culture in the presence of
DMSO (left) or ABA (right) in 91B-Y cells. One nanogram of DNA/reaction used in both cases.
not enough to drive repeat expansion.Rather, our data argue that
DNMT1 has an indirect role in CAG/CTG repeat instability.
To test whether we could detect changes in repeat size within
the same time scale, we tested the effect of known modifiers
of repeat instability. To this end, we cultured GFP(CAG)101 cells
in the presence of doxycycline, which activates transcription
through the repeat tract, or without it for 32 days. We saw

































































































Human Molecular Genetics, 2021, Vol. 00, No. 00 5
Table 1. Small-pool PCR quantification after 30 days of treatment with ABA or DMSO
Cell line Targeting∗ Contractions Expansions Alleles P-value−vs+ ∗∗
91B-Y − 61 (9.5%) 15 (2.3%) 642 0.53
+ 53 (11.5%) 12 (2.6%) 461
89B-Y-DNMT1 − 93 (19.2%) 49 (10.1%) 483 0.78
+ 66 (21.2%) 30 (9.7%) 310
59B-Y-HDAC5 − 0 (0%) 14 (1.5%) 922 0.39
+ 0 (0%) 20 (2.1%) 942
∗: –: DMSO only, +: ABA treated.
∗∗: χ2 test with df = 2 (contractions, expansions, and stable) between−and+ targeting within a cell line. For 59B-Y-HDAC5, we used a Fisher’s exact test.
(Supplementary Material, Fig. S5A). Moreover, the addition of
10 μM of RGFP966, a specific HDAC3 inhibitor (27), abolished
the transcription-dependent expansions and increased H3ac
levels (Supplementary Material, Fig. S5A and B). These results
are consistent with results obtained with other model systems
(1,4,14,28–31), suggesting that our GFP reporter is reliably
monitoring repeat instability. However, these experiments do
not rule out that minor changes in repeat instability may be
missed over that time period.
No evidence for a local role of HDAC5 on repeat
instability
HDAC3 is a class I histone acetyltransferase involved in gene
silencing (33). It works together with the MutSβ complex to
promote CAG/CTG repeat expansion in a human astrocyte cell
line (34,35). Moreover, administration of the HDAC3 inhibitor
RGFP966 to a Huntington’s disease mouse model decreased
repeat expansion (31). Mechanistically, HDAC3 is thought to
function in promoting repeat expansion by deacetylating
MSH3, leading to its import into the nucleus where it can
drive expansions (30). This model predicts that the role of
HDAC3 is largely in trans and therefore targeting it to a repeat
tract using PInT should have little effect on repeat instability.
However, we could not test this hypothesis directly because
we found that PYL-HDAC3 was not fully functional. Indeed,
we expected that the targeting of PYL-HDAC3 would decrease
GFP expression and reduce H3Ac levels. When we generated
stable nB-Y-HDAC3 cells (Supplementary Material, Fig. S6A),
however, we found that targeting PYL-HDAC3 in both 16B-Y-
HDAC3 and 89B-Y-HDAC3 increased GFP expression by 1.5 fold
(Supplementary Material, Fig. S6B, P=0.002 and P=0.02 using a
one-way ANOVA comparing ABA and DMSO treatments in 16B-
Y-HDAC3 and 89B-Y-HDAC3, respectively). The increase in GFP
was accompanied by an efficient targeting of the PYL-HDAC3
fusion (Supplementary Material, Fig. S6C) and an increase in
H3ac levels (Supplementary Material, Fig. S6D). We found that
RGFP966 treatment did not affect the ability of PYL-HDAC3 to
increase GFP expression (Supplementary Material, Fig. S6E).
Moreover, transiently expressing PYL-HDAC3 in GFP-INT-B cells,
without targeting, did not significantly change GFP expression
(Supplementary Material, Fig. S7, P=0.15 using a paired t-test
comparing to controls transfected with PYL only). Together,
these experiments suggest that PYL-HDAC3 does not act as
expected and, thus, we could not use this line to test for a local
role of HDAC3 in repeat instability.
Since HDAC3works together with HDAC5 in repeat instability
(32), we tested whether PYL-HDAC5may be functional and allow
us to test the hypothesis that local recruitment of PYL-HDAC5
impacts repeat instability. HDAC5 is a class IIa deacetylase asso-
ciated with gene silencing and heterochromatin maintenance
(33) as well as cell proliferation (34,35). It is thought to medi-
ate histone deacetylation by recruiting other HDACs, including
HDAC3 (36). We created isogenic nB-Y-HDAC5 cells that stably
express a PYL-HDAC5 fusion and contain 16 or 59 CAG repeats
within the GFP reporter (Fig. 4A). We found that adding ABA to
the culture medium led to an increase in pull-down efficiency of
PYL-HDAC5 at the INT locus from 0.06%±0.03% to 2.2%± 0.2%
in 16B-Y-HDAC5 cells and from 0.1%±0.1% to 3.0%± 0.6% in
59B-Y-HDAC5 (Fig. 4B). PYL-HDAC5 targeting reduced the levels
of acetylated histone H3 (H3Ac), as measured by ChIP-qPCR
(Fig. 4C, P=1.7×10−6 and P=0.039 comparing DMSO- and ABA-
treated 16B-Y-HDAC5 and 59B-Y-HDAC5, respectively, using an
one-way ANOVA), consistent with a functional recruitment of
PYL-HDAC5 to the INT sequence. This was confirmed by tran-
siently transfecting PYL-HDAC5 in GFP-INT cells, which led to
slightly lower GFP expression than those expressing PYL alone
(Supplementary Material, Fig. S4A). Notably, PYL recruitment
led to a marginally significant decrease in H3Ac level in 16B-Y
cells but the decrease was not statistically significant in 91B-
Y cells (Fig. 4D, P=0.04 and P=0.28 comparing the DMSO and
ABA treatments in 16B-Y and 91B-Y cells, respectively, using an
one-way ANOVA). Moreover, we found no significant change in
acetylation upon ABA treatment at the ACTA1 locus in either cell
lines (P>0.09 using a one-way ANOVA comparing H3ac levels
in DMSO and ABA-treated cells). Interestingly, the H3ac levels at
the INT sequencewere similar between 16B-Y and 91B-Y (Fig. 4D,
P=0.44 comparing DMSO-treated 16B-Y and 91B-Y cells using a
one-way ANOVA), suggesting that the H3ac levels are unaffected
by the expansion. Our results show that targeting PYL-HDAC5
reduces the levels of acetylated H3 near the repeat tract.
To monitor the local effect of PYL-HDAC5 targeting on
CAG/CTG repeat instability, we cultured 59B-Y-HDAC5 cells
with ABA or DMSO for 30 days. We found no difference in
allele-size distribution between these two treatments (Fig. 4E,
Supplementary Material, Fig. S4, Table 1, P=0.39 using a
Fisher’s exact test, comparing ABA and DMSO-treated cells for
frequencies of expansions, and P=0.70 using a Mann–Whitney U
test for changes in allele size). Therefore, we find no evidence to
support the hypothesis that HDAC5 promotes repeat expansion
via local changes in protein acetylation around the repeat tract.
Gene silencing efficiency depends on CAG/CTG repeat
length
We originally designed PInT to determine whether factors work
in cis for repeat instability, yet our construct also includes a GFP
reporter that can be used formonitoring gene expression. This is
useful to look for chromatinmodifiers that can silence expanded
repeats. Indeed, finding factors that, upon targeting, can silence
a gene specifically when it bears an expanded allele would open
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Figure 3. Inducible targeting of PYL-DNMT1 leads to changes in CpG methylation. (A) Schematic representation of 16B-Y-DNMT1 (left) and 89B-Y-DNMT1 (right) cell
lines. (B) ChIP-qPCR using antibodies against FLAG to pull down PYL at INT and ACTA1 in 16B-Y-DNMT1 cells (left, N=4) and 89B-Y-DNMT1 cells (right, N=4).after
5-day treatments with ABA or DMSO. The error bars represent the standard error. (C) Bisulfite sequencing showing the percentage of methylated CpG motifs at the INT
sequence in 16B-Y-DNMT1 (left) and 89B-Y-DNMT1 (right) cells in the presence of DMSO alone (black) or ABA (green) after 5-days of continuous ABA or DMSO treatment.
(D) Representative SP-PCR blots after 30 days of continuous culture in the presence of DMSO (left) or ABA (right) in 89B-Y-DNMT1 cells. One nanogram of DNA/reaction
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Figure 4. PYL-HDAC5 targeting reduces acetylation of histone H3. (A) Schematic representation of 16B-Y-HDAC5 (left) and 59B-Y-HDAC5 (right) cells. (B) ChIP-qPCR using
antibodies against FLAG to pull down PYL-HDAC5 at INT and ACTA1 in 16B-Y-HDAC5 cells (left, N=4) and 59B-Y-HDAC5 cells (right, N=4) after a 5-day treatment with
ABA or DMSO. The error bars represent the standard error. (C) ChIP-qPCR data using a pan-acetylated H3 antibody to pull down the INT and ACTA1 loci in 16B-Y-HDAC5
(left, N=4) and 59B-Y-HDAC5 (right, N=4) cells after a 5-day treatment with (A). The error bars represent the standard error. (D) ChIP-qPCR data using a pan-acetylated
H3 antibody to pull down the INT and ACTA1 loci in 16B-Y (left,N=4) and 91B-Y (right,N=4) cells. The error bars represent the standard error. (E) Representative SP-PCR
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Figure 5. Effect of expanded CAG/CTG repeats on targeted epigenome editing.
Mean GFP intensity ratios between ABA and DMSO alone after 5 days of treat-
ment plotted for (A) 16B-Y cells (same data as in Fig. 2C,N=6), 91B-Y cells (same
data as in Fig. 2C,N=6), (B) 16B-Y-DNMT1 (N=4), 89B-Y-DNMT1 (N=4), (C) 16B-Y-
HDAC5 (N=6), and 59B-Y-HDAC5 (N=6). P-values were generated using one-way
ANOVA.
We evaluated whether DNMT1 or HDAC5 targeting could
silence a reporter bearing CAG/CTG repeats using PInT to
measure GFP expression upon ABA addition (Fig. 5A). In 16B-
Y-DNMT1 cells, ABA treatment decreased GFP expression by
2.2-fold compared to DMSO treatment alone. Surprisingly, ABA-
induced silencing was 1.8-fold compared to DMSO alone, or
16% less efficient in 89B-Y-DNMT1 than in 16B-Y-DNMT1 cells.
Although relatively small, the decrease between the two lines
was statistically significant (Fig. 5B, P=0.005 using a one-way
ANOVAcomparing the ratio of themeanGFP expression between
ABA and DMSO-treated cells between the two cell lines). This
was not due to PYL-DNMT1 being targetedmore efficiently upon
ABA addition or leading to higher levels of CpG methylation
around the repeat tract in 16B-Y-DNMT1 cells compared to
89B-Y-DNMT1 cells (Fig. 3B and C). These results rather suggest
that the presence of an expansion reduces the efficiency of
PYL-DNMT1 to silence the reporter.
We next addressed whether this effect was specific to
DNMT1. We added ABA to the medium of 16B-Y-HDAC5 cells
for five days and found a reduction of GFP expression of 2.7-fold
(Fig. 5A). This decrease in expression was significantly smaller
in the context of an expanded repeat (Fig. 5C, Supplementary
Material, Fig. S8, P=0.003 comparing the decrease in expression
upon ABA addition between the 16B-Y-HDAC5 and 59B-Y-HDAC5
using a one-way ANOVA). Some more mundane explanations
were ruled out, including a difference in targeting efficiency
of PYL-HDAC5 or changes in H3Ac levels between the cell
lines (Fig. 4B and C). We also tested whether the allele length-
specific effect on GFP expression required the presence of the
INT sequence. Thus, we transiently expressed PYL-HDAC5 in
GFP(CAG)0B cells, which have no INT in their GFP reporter but
express ParB-ABI. Adding ABA to these cells did not affect GFP
expression (SupplementaryMaterial, Fig. S7), suggesting that the
presence of the INT sequence is essential. Taken together, our
results suggest that expanded CAG repeats resist gene silencing
mediated by both DNMT1 and HDAC5.
The N-terminal domain of HDAC5 mediates silencing
PInT can also be used to delineate the mechanism of gene
silencing upon targeting of a chromatin modifier. To exemplify
this, we sought to clarify how HDAC5 silences the reporter.
Class I HDACs, like HDAC3, derive their catalytic activity in vitro
from a conserved tyrosine residue that helps coordinate a zinc
Figure 6. HDAC5 mediates silencing through its N-terminal. (A) Mutants and
truncations of HDAC5 fused to PYL. The coiled-coil (CC) domain is indicated in
purple, the deacetylase domain (HDAC) in orange. (B) ABA and DMSO treatments
of 40B cells transiently transfected with plasmids containing the constructs
shown in B. Construct 1: N=7, P=0.00001 versus PYL; construct 2: N=7, P=0.006
versus PYL; construct 3: N=7, P=0.001 versus PYL; construct 4: N=7, P=0.88
versus PYL; construct 5: N=7, P=0.0002 versus PYL; construct 6: N=4, P=0.0003
vs PYL. ∗: P≤0.01 compared to PYL targeting. The error bars show the standard
deviation around the mean. P-values were generated using one-way ANOVA.
ion essential for catalysis (35). By contrast, Class IIa enzymes,
like HDAC5, have a histidine instead of tyrosine at the anal-
ogous site, which considerably lowers HDAC activity (35). In
fact, restoring the tyrosine at position 1006 of HDAC5 increases
HDAC activity by over 30-fold (35). We reasoned that if the HDAC
activity was responsible for the silencing activity, the H1006Y
gain-of-function mutant should lead to a more robust silencing.
Moreover, the H1006A mutant, in which the HDAC activity is
dramatically reduced, would not be expected to silence the
reporter. To test these predictions, we transiently transfected
PYL-HDAC5 wild-type as well as H1006Y and H1006A mutants
in 40B cells, which contain the GFP-INT reporter with 40 CAGs
and express ParB-ABI (Fig. 6A). Overall, the effect on silencing
seen upon targeting of the wild-type PYL-HDAC5 fusion was
smaller when delivered by transient transfection compared to
the stable cell lines. Nevertheless, the wild-type PYL-HDAC5
significantly reduced GFP expression compared to PYL alone
(P=0.00001 using a one-wayANOVA). In the same conditions, tar-
geting PYL-HDAC5-H1006A or PYL-HDAC5-H1006Y both silenced
the transgene compared to targeting PYL alone (Fig 6B; P=0.006
and 0.002, respectively, using a one-way ANOVA), suggesting that
tampering with the catalytic activity of HDAC5 does not influ-
ence silencing of our GFP reporter.Moreover, targeting PYL fused
to the catalytic domain of HDAC5 did not shift GFP expression
compared to PYL alone (Fig. 6B, P=0.88 using a one-way ANOVA).
Rather, we find that the silencing activity was contained within
the N-terminal part of HDAC5, which characterizes Class IIa
enzymes. Further truncations (Fig. 6A) are consistent with a
model whereby the coiled-coil domain in the N-terminal part
of HDAC5, which is necessary for homo- and heterodimeriza-
tion of Class IIa enzymes in vitro (37), contains the silencing
activity (Fig. 6B). It may therefore be that this domain recruits
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Figure 7. Allele-size specificity of HDAC5-mediated gene silencing requires
HDAC3 activity. Quantification of GFP intensity upon targeting in the presence
of 10 μM of RGFP966 or untreated (A) 16B-Y (N=6 for each condition) and 91B-Y
cells (N=6 for each condition) and (B) 16B-Y-HDAC5 (N=6 for each condition) and
59B-Y-HDAC5 cells (N=6 for each condition). Note that the data for the untreated
cells are the same as in Figure 5. P-values were generated using one-way ANOVA.
HDAC3 activity is required for the repeat size-specificity
upon HDAC5-mediated silencing
Next, we asked whether PInT could be used to gain insights
into the mechanism of targeted epigenome editing. To do so,
we sought to find enzymatic activities that can modify allele
size-specific silencing brought about by PYL-HDAC5 targeting. To
determine whether the catalytic role of HDAC3 was essential in
HDAC5-mediated silencing, we repeated our experiments in nB-
Y and nB-Y-HDAC5 lines in the presence of the HDAC3 inhibitor
RGFP966 (Fig. 7). We found that RGFP966 had no effect on GFP
expression upon PYL targeting (Fig. 7A) and did not substantially
reduce the ability of PYL-HDAC5 to silence the reporter (Fig. 7B).
However, it abolished the allele-length specificity of PYL-HDAC5
targeting, leading to a silencing efficiency of 2.4- and 2.5-fold
in 16B-Y-HDAC5 and 59B-Y-HDAC5, respectively (Fig. 7B, P=0.78
using a one-way ANOVA). This contrasts with the RGFP966-free
conditionswhere targeting PYL-HDAC5more effectively silenced
the non-pathogenic-sized allele (Fig. 7B).We also used a two-way
ANOVA to test for a significant interaction between repeat size
and RGFP966 treatment.We found one for PYL-HDAC5 but not for
PYL alone (P=0.019 and P=0.20, respectively). These results sug-
gest expanded CAG/CTG repeats impede PYL-HDAC5-mediated
silencing via the catalytic activity of HDAC3.
Discussion
Chromatin structure impinges on every DNA-based transac-
tion, from replication and DNA repair to transcription. Conse-
quently, epigenome editing is being harnessed to understand
basic molecular mechanisms of pathogenesis and for the devel-
opment of novel therapeutic approaches (38). Epigenome edit-
ing is now most commonly carried out by fusing a chromatin
modifying peptide to a catalytically dead Cas9 (dCas9). These
dCas9-based approaches are highly versatile and have been used
successfully to modify disease phenotypes in cells and in vivo
(39,40). PInT is meant to complement dCas9-based approaches.
Specifically, PInT offers two advantages that we have exploited
here. First, it can concentrate a large number of molecules at a
target site (18), independently of chromatin context (17). It is less
practical with dCas9 to recruit equivalent numbers of molecules
at a specific locus as it would require the use of multimerization
domains, in addition to multiple sgRNAs. Second, targeting a
chromatin modifying peptide to different loci can have very
different effects (41,42). This highlights that DNA context affects
epigenome editing in ways that are not currently understood.
Here we designed PInT to isolate expanded repeats tracts from
their endogenous location and concentrate on the effect of
chromatin modifiers. Nonetheless, with PInT it may be possible
to include cis elements next to the repeat tract and evaluate their
effects on instability or gene expression. In fact, PInT may be
used to clone any sequence of interest near the targeting site
and can be utilized for a wide array of applications, beyond the
study of expanded CAG/CTG repeats.
Several studies have suggested that the ectopic insertion of
an expanded CAG/CTG repeat in mice could induce changes in
chromatin structure in the abutting sequences. An early exam-
ple was the random insertion of arrays of transgenes, each
carrying 192 CAGs, which led to the silencing of the transgenes
independently of the site of genomic integration (12). In addition,
inserting a 40 kb human genomic region containing the DMPK
gene along with an expansion of 600 CTGs (11), or a 13.5 Kb
region containing the human SCA7 gene with 92 CAGS (10) all
led to changes in chromatin marks near the expansion. It has
been unclear, however, whether the presence of endogenous
sequence elements, like CpG islands (43) and CTCF-binding sites
(9,44), is necessary for this effect. Our data show that 91 CAGs,
without the flanking sequences normally present at the DMPK
gene fromwhence this repeatwas cloned,does not lead to signif-
icant changes in the levels of H3ac in its vicinity. These data sug-
gest that the flanking sequence elements may play important
roles in the induction and/or maintenance of heterochromatic
marks surrounding expanded CAG/CTG repeats.
PInT can be used to design peptides with enough activity to
be useful in downstream epigenome editing applications. For
instance, here we dissected the mechanisms of action of HDAC5
in silencing using mutants and truncations. We could quickly
screen for domains and mutants that are effective in modulat-
ing gene expression. This is especially desirable in designing
epigenome editing approaches with dCas9 fusions in vivo. A
current limitation of the S. pyogenes Cas9 for in vivo applications
is its large size, which is at the limit of what adeno-associated
viral vectors can accommodate (45). Evenwith the smaller ortho-
logues, packaging a dCas9 fusion inside a gene delivery vector is
a challenge, let alone encoding the sgRNA in the same vector.
Therefore, being able to trim a chromatin modifier down to
its smallest active peptide may help in optimizing downstream
applications and translation.
In this study,we addressed a central question for both HDAC5
andDNMT1 and their involvement in CAG/CTG repeat instability.
It has been unclear what the exact roles of these two enzymes
might be in repeat instability. Specifically, whether they work by
modifying the local chromatin structure or they act in trans has
remained an outstanding issue. For DNMT1, it was speculated
that increases in CpG methylation surrounding the repeat tract
might facilitate repeat expansion (25). The data presented here
do not support such a model and rather point to an indirect role
for DNMT1 in repeat instability, perhaps through changes in the
transcriptome. For example, DNMT1 controls the expression of
MLH1 (46), which has been shown to be important for repeat
instability (47–51). It also remains possible that DNMT1 targeting
did not lead to large enough changes in CpG methylation to
affect repeat instability. The case of HDAC5 is possibly more
complex as its partner, HDAC3, has been shown to play a role
in the deacetylation of MSH3 (30), a known modifier of repeat
instability (14,47,50,52–54). Although we cannot rule out that the
lack of an effect in cis is due to the relatively low frequency of
instability in the 59B-Y-HDAC5 line, the results obtained with
PInT are concordant with a role for HDAC5 in trans. HDAC5 may
help control the deacetylation of MSH3 before it binds to the
repeat tract. Together, these results highlight the usefulness of
PInT in understanding the mechanism of repeat instability.
The observation that expanded CAG/CTG repeats resist gene
silencing is intriguing. This effect appears to be independent
of which silencer is targeted as we have tried two, DNMT1 and
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an HDAC3 inhibitor, RGFP966, that abolishes the difference in
repeat size uponHDAC5 targetingwithout affecting the silencing
activity. Importantly, we cannot currently rule out that RGFP966
may inhibit other HDACs that would be responsible for this
effect.
Epigenome editing, through targeting of PYL-HDAC5 or PYL-
DNMT1, remained unaffected, with similar levels of deacetyla-
tion and DNAmethylation levels regardless of repeat size. These
results suggest that neither H3ac nor DNA methylation are good
proxies for gene silencing. There are several steps towards gene
silencing that could be differentially affected by the presence of
a CAG/CTG repeat expansion. First, transcription is known to be
impeded, at least in vitro, by the presence of a repeat tract (55).
This is counter to the effect on gene silencing that we observed
here. Alternatively, splicing may be differentially regulated by
both the expanded repeats and the targeted epigenome editing.
Indeed, histone marks correlate with changes in splicing pat-
terns (56) and expanded CAG/CTG repeats are known to affect
splicing (23,57). Moreover, both HDAC3 and HDAC5 interact with
splicing factors (58). It is also possible that mRNA or GFP stability
may contribute to the repeat-size-specific effect seen here, but
the mechanism would have to be more convoluted. Ultimately,
finding the HDAC3 target that mediates this effect will help
understanding the mechanism of allele-specific gene silencing
that we uncovered here.
The observations that expanded CAG/CTG repeats reduces
the efficiency of gene silencing has implications in the design
of epigenome editing approaches for expanded repeat disor-
ders. We speculate that PInT may be adapted to screen for
allele length-specific silencers, which may help design novel
therapeutic options for expanded CAG/CTG repeat disorders.
Materials and Methods
Cell culture conditions and cell line construction
Most of the cell lines used, including all the parental lines, were
genotyped by Microsynth, AG (Switzerland) and all confirmed to
be HEK293.2sus. They were free of mycoplasma as assayed by
the Mycoplasma check service of GATC Biotech. The cells were
maintained at 37◦C with 5% CO2 in DMEM containing 10% FBS,
penicillin and streptomycin, as well as the appropriate selection
markers at the following concentrations: 15 μg ml−1 blasticidin,
1 μgml−1 puromycin, 150 μgml−1 hygromycin, 400 μgml−1 G418
and/or 400 μg ml−1 zeocin. Whereas FBS was used to maintain
the cells, dialyzed calf serum was used at the same concentra-
tion for all the experiments presented here. The ABA concentra-
tion used was 500 μM, unless otherwise indicated. Doxycycline
(dox) was used at a concentration of 2 μgml−1 in all experiments.
RGFP966 was used at a concentration of 10 μM. Notably, it is not
possible to obtain several stable lines with the exact same repeat
size as they are, by their nature, highly unstable. This is why we
have lines with different repeat sizes. Furthermore, the sizes can
change over time and upon thawing from the freezer.
A schematic of cell line construction and pedigree is found
in Supplementary Material, Fig. S1, and the lines are listed
in Supplementary Material, Table S1. This table includes the
plasmids made for cell line construction. The levels of the
transgenes are found in Supplementary Material, Fig. S3.
The plasmids used for transient transfections are found in
Supplementary Material, Table S2. For each cell line, single
clones were isolated and tested for expression of ParB-ABI and
PYL-fusions by western blotting using the protocol described
before (16). Briefly, whole cell extracts were obtained, and their
protein content was quantified using the Pierce BCA Protein
Assay Kit (ThermoScientific). Proteins were then run onto Tris-
glycine 10% SDS PAGE gels before being transferred onto nitro-
cellulose membrane (Axonlab). The membranes were blocked
using the Blocking Buffer for Fluorescent Western Blotting
(Rockland), and primary antibodies were added overnight.
Membranes were then washed followed by the addition of the
secondary antibody (diluted 1–2000). The fluorescent signal
was detected using an Odyssey Imaging System (Li-CoR). All
antibodies used are found in Supplementary Material, Table
S3. Unaltered western blot images are found in Supplementary
Material, Fig. S9. To assess repeat sizes, we amplified the repeat
tracts using oVIN-0459 and oVIN-0460 with the UNG and dUTP-
containing PCR as described (59) and then Sanger-sequenced by
Microsynth AG (Switzerland). The sequences of all the primers
used in this study are found in Supplementary Material, Table
S4.
The ParB-INT sequence system used here is the c2 version
described previously (17), except that the ParB protein was
codon-optimized for expression in human cells. It is also called
ANCHOR1 and is distributed by NeoVirTech. ParB-ABI (pBY-
008), PYL (pAB-NEO-PYL), PYL-HDAC5 (pAB(EXPR-PYL-HDAC5-
NEO)) and PYL-HDAC3 (pAB(EXPR-PYL-HDAC3-NEO)) constructs
were randomly inserted and single clones were then isolated
(Supplementary Material, Table S1). GFP-reporter cassettes were
inserted using Flp-mediated recombination according to the
manufacturer’s instruction (Thermo Scientific). Single colonies
were picked and screened for zeocin sensitivity to ensure that
the insertion site was correct. The cell lines, and plasmids
generated and analysed in the current study are available
from the corresponding author. Note that to obtain some of
the plasmids, researchers will also need the permission of
NeoVirTech, which owns the rights to the ANCHOR technology.
Targeting assays
Detailed protocols of the assay and culture conditions can be
found in (60). For targeting assays involving transient trans-
fections, cells were plated onto poly-D-lysine-coated 12-well
plates at a density of 6× 105 cells per well and transfected using
1 μg of DNA per well and Lipofectamine 2000 or Lipofectamine
3000 (Thermofisher Scientific). Six hours after transfection, the
medium was replaced with one containing dox and ABA or
DMSO. Forty-eight hours after the transfection, the cells were
split, and fresh medium with dox and ABA or DMSO was replen-
ished. On the fifth day, samples were detached from the plate
with PBS+1 mM EDTA for flow cytometry analysis.
In the case of the stable cell lines, cells were seeded at a
density of 4×105 per well in 12-well plates. The media included
dox and ABA or DMSO. The medium was changed 48 h later and
left to grow for another 48 h. The cells were then resuspended in
500 μl PBS+1 mM EDTA for flow cytometry analysis.
Flow cytometry
We used an Accuri C6 flow cytometer from BD and measured
the fluorescence in at least 12 500 cells for each treatment. The
raw data were exported as FCS files and analysed using FlowJo
version 10.0.8r1. A full protocol is available here (60).
Chromatin immunoprecipitation
For chromatin immunoprecipitation, the cells were treated as
for the targeting experiments except that we used 10 cm dishes
and 4×106 cells. After 96 h of incubation, paraformaldehydewas
added to themedium to a final concentration of 1% and the cells
were incubated for 10 min at room temperature. The samples
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temperature. Samples were then centrifuged, the supernatant
was discarded, and the cell pellets were washed with ice-cold
PBS twice.The sampleswere split into 107 cell aliquots and either
used immediately or stored at−75◦C for later use. Sonicationwas
done using a Bioruptor for 25–30 min. DNA shearing was visual-
ized by agarose gel electrophoresis after crosslink reversal and
RNase treatment. Twenty percent of sonicated supernatant was
used per IP,with 3 μg anti-FLAG (M2, Sigma), anti–PAN-acetylated
H3 (Merck), or anti-IgG (3E8,SantaCruz Biotechnology) on Protein
G Sepharose 4 Fast Flow beads (GE healthcare). The sampleswere
incubated at 4◦C overnight and then washed with progressively
more stringent conditions. After the IP, the samples were de-
crosslinked and purified using a QIAquick PCR purification kit
(Qiagen) and analysed using a qPCR.
Quantitative PCR
Quantitative PCR was performed with the FastStart Universal
SYBR Green Master Mix (Roche) using a 7900HT Fast Real-Time
PCR System in a 384-Well Block Module (Applied Biosystems™).
Primers used to detect enrichment at the INT sequence and at
ACTA1 gene are listed in Supplementary Material, Table S4. Ct
values were analysed using the SDS Software v2.4. The percent-
age of input reported was obtained by dividing the amount of
precipitated DNA for the locus of interest by the amount in the
input samples multiplied by 100%.
Small-pool PCR
Small-pool PCR experiments were performed on DNA iso-
lated from 91-Y, 59B-Y-HDAC5 and 89B-Y-DNMT1 cells grown
with ABA or DMSO only for 30 days in the presence of the
appropriate selection markers. The SP-PCR protocol used is
described in (59). We used primers oVIN-460 and oVIN-1425
(Supplementary Material, Table S4) to amplify the repeat
tract, ran the products on a TAE agarose gel and alka-
line transferred it on positively charged nylon membrane
(MegaProbe). The membranes were then probed with oVIN-100
(5′-CAGCAGCAGCAGCAGCAGCAGCAGCAGCAG) that was end-
labelled with 32P and exposed to a phosphoscreen and scanned
with a Typhoon scanner. For each sample, we first performed
serial dilutions to obtain the concentration of amplifiable
alleles.We calculated that concentration by using the number of
reactions that led to no amplification and used that probability
to calculate the average number of alleles per PCR using a
Poisson distribution as described (26).We used between 2 and 20
alleles per reaction for the quantifications seen in Table 1 and
Supplementary Material, Fig. S4. To quantify repeat instability,
membranes were blinded, and a different lab member drew
lines at the top and bottom of the most common bands and
then counted individual alleles that fell outside of these lines.
The number of alleles that contracted or expanded were divided
by the total number of alleles amplified as estimated using a
Poisson distribution. To look for the changes in the size of the
repeat tract, we used a 1 kb DNA ladder to bin the repeats
according to their size. Note that we could detect smaller
changes in repeat size in the instability analyses shown in
Table 1 where we quantified expansions, contractions, and no
change, used the most common allele as a reference point.
Consequently, in the case where we quantify the change in
repeat size (SupplementaryMaterial, Fig. S4),we had lower levels
of instability. Moreover, we had fewer alleles analysed as two
gels were not photographed prior to transfer onto a membrane
and could not be analysed adequately. Unaltered small-pool
PCR blots are found in Supplementary Material, Fig. S10. We
have noted that cell lines with repeats that are mildly expanded
(e.g. 59 CAGs) have fewer contractions than longer ones. This is
consistent with studies in the context of DM1 and HD (61), albeit
the size threshold for seeing more contractions may be shorter
in HEK293-derived cells than in mice.
Bisulfite sequencing
Bisulfite conversion was done using the EZ DNA Methylation
kit from Zymo Research as described before (13). We converted
200 ng of DNA at 50◦C for 12 h from each cell line after 30 days
of culturing with ABA. We used primer oVIN-2209 and oVIN-
2211 to amplify the converted DNA (Supplementary Material,
Table S4). The products were then purified using the NucleoSpin
PCR Clean-up kit (Macherey-Nagel). We then performed 2×250
bp paired-end MiSeq sequencing (Illumina). The sequencing
primers are found in Supplementary Material, Table S4. We
processed the reads with TrimGalore (github.com/FelixKrueger/
TrimGalore) using -q 20—length 20 –paired.We aligned the reads
using QuasR (62) to the GFP transgene sequence. We extracted
the methylation levels for each CpG in the amplicon with the
qMeth() function in QuasR. We calculated the CpG methylation
frequencies by dividing the frequency ofmethylated CpGs by the
total number of CpG and expressed it as a percentage.
Statistics
We determined statistical significance in the targeting and ChIP
experiments using a two-tailed one-way ANOVA. For small-pool
PCR we used a χ2 test with two degrees of freedom using three
categories: expansions, contractions and no change. We used a
Fisher’s exact test in the case of the 59B-Y-HDAC5 lines because
we found no contractions. Most statistical analyses were done
using R studio version 3.4.0, with the exception of the two-way
ANOVA, the paired t-tests, and the MannWhitney U tests, which
were done using GraphPad Prims version 8.4.2. We concluded
that there was a significant difference when P<0.05.
Supplementary Material
Supplementary Material is available at HMG online.
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